Fig. 1
From: Expression of TRAF6 in peripheral blood B cells of patients with myasthenia gravis
A Comparison of the TRAF6-positive ratio in CD19+ B cells among different groups (HCs: 0.89 (0.36, 1.45), MG: 1.94 (1.018, 3.773), p < 0.01; acute aggravation state: OMG: 1.76 (0.83, 3.26), GMG: 3.23 (1.51, 6.70), p = 0.03). Acute refers MG patients with acute aggravation state but before any immunotherapy. TRAF6 expression was significantly elevated in CD19+ B cells and CD19+ CD27+ memory B cells in GMG with acute aggravation compared with GMG in MMS (p = 0.009, p = 0.028 respectively). MMS patients were those who had achieved a minimal manifestation state (MMS) after immunotherapy or nonimmunotherapy. B Comparison of the TRAF6-positive ratio in CD19+CD27+ B cells among different groups (HCs: 0.27 (0.16, 1.57), MG: 2.25 (0.77, 4.42), p < 0.01; acute aggravation state: OMG: 1.94 (0.68, 3.38), GMG: 3.23 (1.61, 6.45), p = 0.03). C Flow cytometry analysis of TRAF6 in CD19+ B cells from healthy controls (HCs), ocular myasthenia gravis (OMG) patients and generalized myasthenia gravis (GMG) patients with acute aggravation. D Flow cytometry analysis of TRAF6 in CD19+CD27+ memory B cells from HCs, OMG patients and GMG patients with acute aggravation